| Schedule of Segment Information |
Segment
information for the three months ended June 30, 2026 is presented below:
Schedule
of Segment Information
| | |
Pharmaceutical
Operations | | |
Premium
Nutritional
Supplements | | |
Total
Reportable
Segments | | |
Corporate
/ Other | | |
Total | |
| Revenue | |
| - | | |
| 24,245 | | |
| 24,245 | | |
| - | | |
| 24,245 | |
| Cost of goods sold | |
| - | | |
| 3,181 | | |
| 3,181 | | |
| - | | |
| 3,181 | |
| Research and development | |
| 600,353 | | |
| - | | |
| 600,353 | | |
| - | | |
| 600,353 | |
| Selling, general and administrative | |
| 503,223 | | |
| 386,645 | | |
| 889,868 | | |
| 1,273,788 | | |
| 2,163,656 | |
| Segment net loss | |
| (1,103,576 | ) | |
| (365,581 | ) | |
| (1,469,157 | ) | |
| (1,273,788 | ) | |
| (2,742,945 | ) |
| Other interest income (expense), net | |
| - | | |
| - | | |
| - | | |
| 468,548 | | |
| 468,548 | |
| Net loss | |
| (1,103,576 | ) | |
| (365,581 | ) | |
| (1,469,157 | ) | |
| (805,240 | ) | |
| (2,274,397 | ) |
Segment
information for the six months ended June 30, 2026 is presented below:
| | |
Pharmaceutical
Operations | | |
Premium
Nutritional
Supplements | | |
Total
Reportable
Segments | | |
Corporate
/ Other | | |
Total | |
| Revenue | |
| - | | |
| 42,897 | | |
| 42,897 | | |
| - | | |
| 42,897 | |
| Cost of goods sold | |
| - | | |
| 7,543 | | |
| 7,543 | | |
| - | | |
| 7,543 | |
| Research and development | |
| 1,011,402 | | |
| - | | |
| 1,011,402 | | |
| - | | |
| 1,011,402 | |
| Selling, general and administrative | |
| 705,531 | | |
| 856,526 | | |
| 1,562,057 | | |
| 2,167,840 | | |
| 3,729,897 | |
| Segment net loss | |
| (1,716,933 | ) | |
| (821,172 | ) | |
| (2,538,105 | ) | |
| (2,167,840 | ) | |
| (4,705,945 | ) |
| Other interest income (expense), net | |
| - | | |
| - | | |
| - | | |
| 369,590 | | |
| 369,590 | |
| Net loss | |
| (1,716,933 | ) | |
| (821,172 | ) | |
| (2,538,105 | ) | |
| (1,798,250 | ) | |
| (4,336,355 | ) |
|